Lu Panrui, Cheng Yalong, Xue Lei, Ren Xintong, Xu Xilong, Chen Chenglong, Cao Longzhi, Li Jiaojiao, Wu Qingcui, Sun Shan, Hou Junjie, Jia Wei, Wang Wei, Ma Yan, Jiang Zhaodi, Li Chao, Qi Xiangbing, Huang Niu, Han Ting
Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing 102206, China; National Institute of Biological Sciences, Beijing 102206, China.
National Institute of Biological Sciences, Beijing 102206, China; College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Cell. 2024 Dec 12;187(25):7126-7142.e20. doi: 10.1016/j.cell.2024.10.015. Epub 2024 Nov 1.
Targeted protein degradation (TPD) utilizes molecular glues or proteolysis-targeting chimeras (PROTACs) to eliminate disease-causing proteins by promoting their interaction with E3 ubiquitin ligases. Current TPD approaches are limited by reliance on a small number of constitutively active E3 ubiquitin ligases. Here, we report that (S)-ACE-OH, a metabolite of the antipsychotic drug acepromazine, acts as a molecular glue to induce an interaction between the E3 ubiquitin ligase TRIM21 and the nucleoporin NUP98, leading to the degradation of nuclear pore proteins and disruption of nucleocytoplasmic trafficking. Functionalization of acepromazine into PROTACs enabled selective degradation of multimeric proteins, such as those within biomolecular condensates, while sparing monomeric proteins. This selectivity is consistent with the requirement of substrate-induced clustering for TRIM21 activation. As aberrant protein assemblies cause diseases such as autoimmunity, neurodegeneration, and cancer, our findings highlight the potential of TRIM21-based multimer-selective degraders as a strategy to tackle the direct causes of these diseases.
靶向蛋白质降解(TPD)利用分子胶或蛋白酶靶向嵌合体(PROTAC),通过促进致病蛋白与E3泛素连接酶的相互作用来消除这些蛋白。目前的TPD方法受到依赖少数组成型活性E3泛素连接酶的限制。在此,我们报告抗精神病药物乙酰丙嗪的代谢产物(S)-ACE-OH作为一种分子胶,诱导E3泛素连接酶TRIM21与核孔蛋白NUP98之间的相互作用,导致核孔蛋白降解并破坏核质运输。将乙酰丙嗪功能化制成PROTAC能够选择性降解多聚体蛋白,如生物分子凝聚物中的那些蛋白,同时保留单体蛋白。这种选择性与TRIM21激活所需的底物诱导聚集一致。由于异常蛋白质聚集体会引发自身免疫、神经退行性疾病和癌症等疾病,我们的研究结果突出了基于TRIM21的多聚体选择性降解剂作为解决这些疾病直接病因策略的潜力。